Compare ADT Inc (ADT) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs Amylx Pharmaceuticals Inc — how do they compare? ADT Inc trades at $7.34 (market cap $5.44B), while Amylx Pharmaceuticals Inc trades at $23.64 (market cap $2.64B). The key difference: ADT Inc is far larger — about 2.1× Amylx Pharmaceuticals Inc's market cap, and ADT Inc pays a 2.95% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ADT | AMLX | |
|---|---|---|
Market Cap | $5.44B | $2.64B |
Sector | Industrials | Health |
52-Week High | $8.85 | $24.19 |
52-Week Low | $6.30 | $7.82 |
Enterprise Value | $13.13B | $2.39B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $7.31, down 2.66% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows solid fundamentals with a P/E of 10.35, net income margin of 11.86%, and consistent revenue growth, supported by positive analyst sentiment and institutional buying.
Outlook remains positive due to strong cash flow, dividend payments, and AI integration, but risks include high debt levels and competitive pressures. Wall Street consensus leans bullish with 47% buy ratings, suggesting potential upside if execution continues.
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
